Previous 10 | Next 10 |
2023-03-30 13:19:05 ET Inventiva S.A. (IVA) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman ...
2023-03-29 16:08:56 ET Inventiva press release ( NASDAQ: IVA ): FY GAAP EPS of -€1.31 misses by €0.02 . Revenue of €12.18M (+190.7% Y/Y) misses by €0.44M . Other income amounted to €6.6 million for the full year 2022, as ...
Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis, announced the receipt of the €25M payment under the first tranche of the unsecured loan agreement executed with the Eur...
Inventiva ( NASDAQ: IVA ) ( OTCPK:IVEVF ) said AbbVie ( NYSE: ABBV ) has decided to stop the development of cedirogant (ABBV-157) to treat autoimmune diseases after analysis of a nonclinical toxicology study. In 2012, the two companies entered a collab...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! There’s major marijuana news moving stocks thi...
Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...
Inventiva S.A. (IVA) Q2 2022 Earnings Conference Call September 22, 2022, 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial ...
Inventiva press release ( NASDAQ: IVA ): 1H GAAP EPS of -$0.72. Revenue of $67K (-51.8% Y/Y). For further details see: Inventiva GAAP EPS of -$0.72, revenue of $67M
France-based clinical-stage biopharma Inventiva ( NASDAQ: IVA ) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. ...
Inventiva press release (NASDAQ:IVA): Cash position at €80.5m as of March 31, 2022 The Group did not generate any revenue in Q1 2022 Signature of a €50 million bullet credit facility agreement with the European Investment Bank For further details see: Inventiva r...
News, Short Squeeze, Breakout and More Instantly...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...